Last updated: September 7, 2026
Osimertinib mesylate, marketed by AstraZeneca as Tagrisso, is one of the company’s largest oncology products and the leading targeted therapy for EGFR-mutated non-small-cell lung cancer. Its commercial base has expanded from metastatic disease into adjuvant treatment and unresectable stage III disease after chemoradiotherapy. Product sales increased from approximately $4.3 billion in 2020 to roughly $6.5 billion in 2024, with further growth dependent on earlier-line treatment, global penetration and regulatory expansion.[1-5]
The principal commercial risk is delayed generic entry rather than biosimilar competition. AstraZeneca’s core composition-of-matter patent is expected to protect U.S. sales into the early 2030s, while formulation and method-of-use patents may extend legal exposure in selected indications. Generic challenges have been filed, but the timing of launch depends on Paragraph IV litigation, settlement terms, patent validity and the scope of enforceable claims.
What is osimertinib mesylate and how is Tagrisso used?
Osimertinib is an irreversible third-generation epidermal growth factor receptor tyrosine kinase inhibitor. The active moiety is osimertinib; the commercial product is osimertinib mesylate.
| Attribute |
Detail |
| Brand |
Tagrisso |
| Active ingredient |
Osimertinib mesylate |
| Originator |
AstraZeneca |
| Drug class |
EGFR tyrosine kinase inhibitor |
| Primary disease |
EGFR-mutated NSCLC |
| Key mutations |
EGFR exon 19 deletion, L858R and selected resistance mutations |
| U.S. dosage form |
40 mg and 80 mg tablets |
| Administration |
Once daily |
| U.S. first approval |
November 2015 |
| Core diagnostic requirement |
FDA-approved companion diagnostic testing for EGFR mutations |
Osimertinib selectively targets sensitizing EGFR mutations and the T790M resistance mutation. Its central commercial advantage is central nervous system activity, which supports use in patients with or at risk for brain metastases.
The product initially gained approval for metastatic EGFR T790M-positive NSCLC after progression on EGFR therapy. FDA approval later expanded to first-line metastatic disease, adjuvant treatment after tumor resection and unresectable stage III disease following concurrent or sequential chemoradiotherapy.[6-9]
How has osimertinib revenue changed over time?
Tagrisso revenue has followed a sustained upward trajectory as AstraZeneca moved the product from a salvage therapy into earlier disease settings.
| Fiscal year |
Approximate Tagrisso product sales |
Main commercial driver |
| 2020 |
$4.3 billion |
First-line metastatic use |
| 2021 |
$5.0 billion |
Global adoption and CNS efficacy |
| 2022 |
$5.4 billion |
Broader first-line penetration |
| 2023 |
$5.8 billion |
Continued volume growth |
| 2024 |
Approximately $6.5 billion |
Adjuvant uptake and expanded disease settings |
Sources: AstraZeneca annual reports and full-year financial releases.[1-5]
The revenue profile has four structural supports:
- First-line treatment has replaced the earlier T790M-only market as the principal revenue base.
- The ADAURA approval created an adjuvant market in resected EGFR-mutated NSCLC.
- The LAURA-based approval created a post-chemoradiotherapy market in unresectable stage III disease.
- AstraZeneca has increased testing and treatment penetration in China, Europe and other international markets.
The product remains exposed to price controls, reimbursement restrictions and foreign-exchange movements. The U.S. market has a higher revenue contribution per treated patient, while China is strategically important because of the size of the EGFR-mutated NSCLC population and the greater role of centralized procurement and negotiated pricing.
When does osimertinib lose exclusivity in the United States?
The practical U.S. exclusivity date is not determined by one patent alone. It depends on the earliest enforceable generic entry date after patent litigation, settlement and any regulatory exclusivity.
| Protection category |
Representative protection |
Commercial significance |
| Active-ingredient patents |
U.S. patents covering osimertinib and related compounds |
Principal barrier to early generic launch |
| Formulation patents |
Patents covering tablet composition and pharmaceutical formulations |
May support later or indication-specific barriers |
| Method-of-use patents |
Patents covering treatment of EGFR-mutated NSCLC and specific disease settings |
Can restrict labeled generic use, but may not block all market entry |
| Regulatory exclusivity |
New chemical entity, supplemental approvals and pediatric provisions where applicable |
Separate from patent protection |
The foundational U.S. patent generally associated with osimertinib is U.S. Patent No. 8,969,373. Public patent records identify AstraZeneca affiliates as the relevant assignees and show protection extending into the early 2030s after applicable patent-term adjustment.[10]
The core composition patent is the strongest single barrier because it covers the drug substance rather than only a particular indication. Later patents may extend protection for tablets, formulations or treatment methods, but their ability to prevent full generic substitution depends on claim scope and whether the generic product can omit the protected indication from its label.
A precise commercial forecast should distinguish:
- the earliest date on which an ANDA applicant may obtain approval;
- the date on which a generic may launch without infringing an enforceable patent;
- the date on which a generic could obtain broad substitution through pharmacy channels; and
- the date on which all meaningful patent barriers expire.
For Tagrisso, broad U.S. generic competition is more likely to be a post-2030 event, with the core composition-of-matter patent representing the principal timing constraint. Later formulation and method patents may create additional litigation risk through the mid-2030s, but they do not automatically guarantee a product-wide extension.
What is the Orange Book status of Tagrisso?
Tagrisso is an FDA-approved small-molecule drug listed in the Orange Book. Orange Book-listed patents may include drug-substance, drug-product and method-of-use claims submitted by AstraZeneca.[11]
The Orange Book is commercially important because an ANDA applicant must certify against listed patents. A Paragraph IV certification alleges that a listed patent is invalid, unenforceable or not infringed. The certification can trigger patent litigation and, if suit is filed within the statutory period, an FDA approval stay of up to 30 months, subject to statutory exceptions and court developments.
Orange Book protection should be assessed at the product level:
| Question |
Relevance to Tagrisso |
| Is the active ingredient listed? |
Yes, as osimertinib mesylate |
| Is the product a biologic? |
No |
| Is biosimilar approval available? |
No |
| Can an ANDA be filed? |
Yes, subject to the Hatch-Waxman pathway |
| Can use patents be listed? |
Yes, if they satisfy FDA listing requirements |
| Does every listed patent block all generic use? |
No |
The Orange Book listing alone does not establish that every patent will survive litigation. Validity, infringement and enforceability remain separate legal questions.
Which companies are challenging osimertinib patents?
Generic manufacturers have commercial incentives to challenge Tagrisso because the product has multibillion-dollar annual sales and a well-defined tablet dosage form. Publicly reported ANDA litigation has involved generic drug companies, including applicants such as Natco and other manufacturers that have disputed AstraZeneca patent rights in U.S. federal court.
The main litigation theories in Paragraph IV cases typically include:
- lack of novelty;
- obviousness;
- inadequate written description;
- lack of enablement;
- noninfringement of composition or formulation claims;
- invalidity of method-of-use claims; and
- improper or incomplete Orange Book listing.
The litigation risk is asymmetric. A generic applicant may challenge the foundational compound patent to obtain a launch opportunity, while AstraZeneca may rely on secondary patents to preserve protection if the core patent is narrowed or invalidated.
What patent litigation and settlement risks affect generic entry?
AstraZeneca’s likely litigation posture is to defend the active-ingredient patent while asserting formulation and use patents where the ANDA product or proposed label creates a credible infringement theory.
Settlement agreements can produce one of three outcomes:
- An agreed launch date before full patent expiry.
- A licensed entry date linked to a fixed calendar date.
- Continued litigation without a public commercial settlement.
The financial effect of a settlement depends on whether entry is authorized, volume-limited, royalty-bearing or subject to a later launch date. A settlement that permits one generic manufacturer to enter before patent expiry can accelerate price erosion even if broad competition remains restricted.
No public settlement should be treated as evidence of invalidity unless its terms or subsequent court action establish that result. Hatch-Waxman settlements often preserve significant value for both parties by defining a controlled launch date.
How strong is the osimertinib patent estate?
The estate is strong in commercial terms because it combines a core small-molecule patent with multiple secondary protection categories and a large installed patient base.
Core compound protection
The composition-of-matter patent is the highest-value asset. A valid claim to osimertinib or a closely defined pharmaceutically acceptable salt can block ANDA products containing the same active ingredient.
Formulation protection
Formulation patents may cover:
- tablet compositions;
- excipient combinations;
- chemical stability;
- dissolution profiles;
- solid-state or salt characteristics; and
- manufacturing processes.
Formulation patents are generally weaker than compound patents when the generic can design around the claimed formulation. They become more important after the compound patent expires.
Method-of-use protection
AstraZeneca has expanded the clinical label across metastatic, adjuvant and locally advanced disease. Method patents may cover treatment of patients with specified EGFR mutations, disease stages or prior-treatment histories.
Use patents can limit a generic’s labeled indications. They do not always prevent physicians from prescribing a generic for an unpatented use, and they may be vulnerable to induced-infringement disputes.
Manufacturing and know-how barriers
Manufacturing protection may cover intermediates, synthetic routes, impurity control and crystallization. These rights can raise development costs, but process patents generally provide less durable market protection than a valid compound patent because generic manufacturers can develop noninfringing routes.
What is the FDA regulatory status of osimertinib?
| FDA milestone |
Date |
| Accelerated approval for metastatic EGFR T790M-positive NSCLC |
November 2015 |
| Full approval for T790M-positive disease |
March 2017 |
| First-line metastatic EGFR-mutated NSCLC |
April 2018 |
| Adjuvant treatment after resection |
December 2020 |
| Unresectable stage III EGFR-mutated NSCLC after chemoradiotherapy |
September 2024 |
The 2020 adjuvant approval materially expanded the addressable population because patients can receive osimertinib after surgery before metastatic recurrence. The 2024 stage III indication further moved treatment into earlier disease and increased the number of patients eligible for long-duration therapy.[7-9]
The regulatory expansion is commercially more important than a conventional line extension because it increases treatment duration and moves the product into settings where physicians may treat patients for years rather than until progression.
Is there biosimilar risk for osimertinib?
There is no biosimilar risk because osimertinib is a chemically synthesized small molecule, not a biologic. Competition will arise through the ANDA generic pathway.
The primary post-exclusivity risks are:
- multiple ANDA approvals;
- authorized generic competition;
- price reductions from pharmacy benefit managers;
- therapeutic substitution;
- payer restrictions favoring lower-cost EGFR inhibitors; and
- generic launches in markets with weaker patent enforcement.
The commercial erosion curve could be steep if several manufacturers enter simultaneously. It could be slower if AstraZeneca reaches an authorized-generic arrangement or if secondary patents delay broad substitution.
How does osimertinib compare with competing EGFR drugs?
| Drug |
Company |
EGFR positioning |
Competitive effect |
| Osimertinib |
AstraZeneca |
Third-generation, CNS-active, broad first-line and adjuvant use |
Market leader |
| Erlotinib |
Roche/Genentech and generics |
Earlier-generation EGFR inhibitor |
Low-cost comparator |
| Gefitinib |
AstraZeneca and generics |
Earlier-generation EGFR inhibitor |
Price-driven alternative |
| Afatinib |
Boehringer Ingelheim and generics |
Irreversible ErbB-family inhibitor |
Alternative in selected patients |
| Lazertinib |
Janssen/Johnson & Johnson and partners |
Third-generation EGFR inhibitor |
Direct branded competitor |
| Amivantamab combinations |
Johnson & Johnson |
Antibody-based EGFR/MET strategy |
Combination and resistance-market competition |
Lazertinib is the most direct branded competitor in the third-generation EGFR segment. Amivantamab-based regimens compete in first-line and resistance settings, but their administration burden and combination profile differ from once-daily oral osimertinib.
Osimertinib retains advantages in clinical familiarity, CNS evidence, broad regulatory labeling and established diagnostic workflows. Competition may become more material in newly diagnosed patients if combination regimens improve progression-free or overall survival.
What licensing deals affect osimertinib?
Osimertinib is primarily an AstraZeneca-controlled product. Its commercial trajectory has not depended on a major external co-development or co-commercialization transaction comparable with AstraZeneca’s Enhertu collaboration with Daiichi Sankyo.
Regional commercialization, distribution and manufacturing arrangements may affect supply and market access, particularly in China and other regulated markets. Those arrangements should be distinguished from a patent license. A distribution agreement does not necessarily provide the counterparty with rights to challenge or practice AstraZeneca’s patent estate.
What generic launch scenarios exist for Tagrisso?
Scenario 1: Core patent upheld
Generic entry remains restricted until the core patent expires or a settlement permits an earlier launch. Revenue continues to grow or remains stable through the late 2020s, supported by earlier-line indications.
Scenario 2: Core patent invalidated
Multiple ANDA applicants could enter after FDA approval, producing rapid price and volume erosion. Secondary patents could still create partial barriers, but they would be less likely to preserve the existing revenue base.
Scenario 3: Controlled settlement entry
One or more manufacturers receive a negotiated launch date. AstraZeneca preserves substantial pre-expiry revenue, while generic competition begins before the full patent estate expires.
Scenario 4: Staggered market entry
A first generic enters under a narrow label or settlement, followed by broader competition after additional patents expire. Revenue declines in steps rather than in one event.
What geographic markets create the greatest exposure?
The United States is the most important market for patent-driven revenue exposure because of high treatment value and strong ANDA substitution mechanics. Europe has a more fragmented patent and reimbursement environment, with market entry governed by national validation, litigation and pricing procedures.
China has a large EGFR-mutated patient population but greater exposure to negotiated pricing, reimbursement listing and centralized procurement. Patent protection and regulatory timing can differ substantially from the United States.
Japan and other developed markets provide durable demand but may show slower revenue growth because of smaller populations and local reimbursement controls. Emerging markets can expand patient volume while contributing lower net price per treatment course.
Key Takeaways
- Osimertinib mesylate is AstraZeneca’s Tagrisso, a leading EGFR-targeted NSCLC therapy.
- Revenue rose from approximately $4.3 billion in 2020 to about $6.5 billion in 2024.
- Growth has shifted from metastatic salvage treatment to first-line, adjuvant and post-chemoradiotherapy use.
- The principal U.S. barrier is the composition-of-matter patent, with protection expected into the early 2030s.
- Formulation and method-of-use patents may extend litigation and delay broad substitution, but their blocking power is narrower.
- Generic rather than biosimilar competition will determine post-exclusivity erosion.
- The largest financial variable is whether Paragraph IV litigation produces unrestricted, controlled or delayed generic entry.
- The 2024 stage III approval expands the treatment population and supports revenue durability before generic launch.
FAQs about osimertinib mesylate market and patent exposure
What is the generic name for Tagrisso?
The generic name is osimertinib, supplied commercially as osimertinib mesylate.
Is osimertinib a chemotherapy drug?
No. It is an oral targeted EGFR tyrosine kinase inhibitor.
How long do patients usually take osimertinib in the adjuvant setting?
The approved adjuvant regimen is generally administered for up to three years, subject to recurrence, toxicity and clinical judgment.[7]
Can generic osimertinib launch before the core patent expires?
Yes, but only through a successful patent challenge, a settlement license, an authorized-generic arrangement or another legally permitted pathway.
Will biosimilars reduce Tagrisso revenue?
No. Biosimilars apply to biologic products. Tagrisso faces small-molecule generic competition through the ANDA pathway.
References
- AstraZeneca. (2021). Annual report and Form 20-F 2020.
- AstraZeneca. (2022). Annual report and Form 20-F 2021.
- AstraZeneca. (2023). Annual report and Form 20-F 2022.
- AstraZeneca. (2024). Annual report and Form 20-F 2023.
- AstraZeneca. (2025). Full-year and fourth-quarter 2024 results.
- U.S. Food and Drug Administration. (2015). FDA approves new treatment for certain patients with non-small cell lung cancer.
- U.S. Food and Drug Administration. (2020). FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer.
- U.S. Food and Drug Administration. (2018). FDA approves osimertinib for first-line treatment of metastatic NSCLC.
- U.S. Food and Drug Administration. (2024). FDA approves osimertinib with or without chemotherapy for unresectable stage III EGFR-mutated NSCLC.
- U.S. Patent No. 8,969,373. (2015). N-substituted indole derivatives as inhibitors of mutant EGFR.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
